{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:53:44Z","timestamp":1791294824610,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Amgen Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"DOI":"10.1007\/s40123-026-01516-9","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:53:56Z","timestamp":1791291236000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Post Hoc MRI Analysis of Orbital Soft Tissue Volumes Pre- and Post-Teprotumumab in Patients with Chronic, Low-Activity Thyroid Eye Disease"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4479-3033","authenticated-orcid":false,"given":"Shoaib","family":"Ugradar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ada","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Karon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenxun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prem S.","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara T.","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"issue":"suppl 1","key":"1516_CR1","doi-asserted-by":"publisher","first-page":"S36","DOI":"10.1210\/clinem\/dgac168","volume":"107","author":"AL Kossler","year":"2022","unstructured":"Kossler AL, Douglas R, Dosiou C. Teprotumumab and the evolving therapeutic landscape in thyroid eye disease. J Clin Endocrinol Metab. 2022;107(suppl 1):S36\u201346.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"1516_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1001\/jamaophthalmol.2022.3225","volume":"141","author":"TJ Smith","year":"2023","unstructured":"Smith TJ, Cockerham K, Lelli G, et al. Utility assessment of moderate to severe thyroid eye disease health states. JAMA Ophthalmol. 2023;141(2):159\u201366.","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"1516_CR3","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1210\/clinem\/dgad637","volume":"109","author":"RS Douglas","year":"2023","unstructured":"Douglas RS, Couch S, Wester ST, et al. Efficacy and safety of teprotumumab in patients with thyroid eye disease of long duration and low disease activity. J Clin Endocrinol Metab. 2023;109(1):25\u201335.","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"1516_CR4","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1007\/s40618-023-02036-0","volume":"46","author":"M Pelewicz-Sowa","year":"2023","unstructured":"Pelewicz-Sowa M, Mi\u015bkiewicz P. Dysthyroid optic neuropathy: emerging treatment strategies. J Endocrinol Invest. 2023;46(7):1305\u201316.","journal-title":"J Endocrinol Invest"},{"issue":"9","key":"1516_CR5","doi-asserted-by":"publisher","DOI":"10.1097\/GOX.0000000000003809","volume":"9","author":"S Ugradar","year":"2021","unstructured":"Ugradar S, Braun J, Wang Y, Zimmerman E, Douglas RS. Facial and eyelid changes in thyroid eye disease are reversed by teprotumumab. Plast Reconstr Surg Glob Open. 2021;9(9):e3809.","journal-title":"Plast Reconstr Surg Glob Open"},{"issue":"3","key":"1516_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1001\/archopthalmol.2011.1271","volume":"130","author":"KI Papageorgiou","year":"2012","unstructured":"Papageorgiou KI, Hwang CJ, Chang SH, et al. Thyroid-associated periorbitopathy: eyebrow fat and soft tissue expansion in patients with thyroid-associated orbitopathy. Arch Ophthalmol. 2012;130(3):319\u201328.","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"1516_CR7","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1097\/IOP.0000000000000015","volume":"30","author":"CM Bingham","year":"2014","unstructured":"Bingham CM, Harris MA, Realini T, Nguyen J, Hogg JP, Sivak-Callcott JA. Calculated computed tomography volumes of lacrimal glands and comparison to clinical findings in patients with thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2014;30(2):116\u20138.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"5","key":"1516_CR8","doi-asserted-by":"publisher","first-page":"319","DOI":"10.3341\/kjo.2016.30.5.319","volume":"30","author":"HD Huh","year":"2016","unstructured":"Huh HD, Kim JH, Kim SJ, Yoo JM, Seo SW. The change of lacrimal gland volume in Korean patients with thyroid-associated ophthalmopathy. Korean J Ophthalmol. 2016;30(5):319\u201325.","journal-title":"Korean J Ophthalmol"},{"issue":"3","key":"1516_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1089\/105072502753600205","volume":"12","author":"GJ Kahaly","year":"2002","unstructured":"Kahaly GJ, Hardt J, Petrak F, Egle UT. Psychosocial factors in subjects with thyroid-associated ophthalmopathy. Thyroid. 2002;12(3):237\u20139.","journal-title":"Thyroid"},{"issue":"9","key":"1516_CR10","doi-asserted-by":"publisher","DOI":"10.1530\/EC-24-0259","volume":"13","author":"WKW Al-Badri","year":"2024","unstructured":"Al-Badri WKW, Jellema HM, Potvin A, van Nispen RMA, Bisschop PH, Saeed P. Psychological aspects of Graves\u2019 ophthalmopathy. Endocr Connect. 2024;13(9):e240259.","journal-title":"Endocr Connect"},{"issue":"8","key":"1516_CR11","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41433-021-01593-z","volume":"36","author":"S Ugradar","year":"2022","unstructured":"Ugradar S, Kang J, Kossler AL, et al. Teprotumumab for the treatment of chronic thyroid eye disease. Eye (Lond). 2022;36(8):1553\u20139.","journal-title":"Eye (Lond)"},{"issue":"4","key":"1516_CR12","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40259-025-00726-0","volume":"39","author":"S Ugradar","year":"2025","unstructured":"Ugradar S, Parunakian E, Douglas RS. The use of biologics for thyroid eye disease. BioDrugs. 2025;39(4):607\u201319.","journal-title":"BioDrugs"},{"issue":"7","key":"1516_CR13","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1038\/s41433-021-01904-4","volume":"36","author":"CY Yu","year":"2022","unstructured":"Yu CY, Simmons BA, Pham CM, Shriver EM. The role of teprotumumab in chronic, clinically active thyroid eye disease. Eye (Lond). 2022;36(7):1500\u20131.","journal-title":"Eye (Lond)"},{"issue":"9","key":"1516_CR14","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/j.eprac.2022.06.003","volume":"28","author":"Y Wang","year":"2022","unstructured":"Wang Y, Padnick-Silver L, Francis-Sedlak M, Holt RJ, Foley C, Douglas RS. Inflammatory and noninflammatory thyroid eye disease: comparison of disease signs, symptoms, and quality of life in patients in the United States. Endocr Pract. 2022;28(9):842\u20136.","journal-title":"Endocr Pract"},{"issue":"4","key":"1516_CR15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s40123-021-00385-8","volume":"10","author":"KP Cockerham","year":"2021","unstructured":"Cockerham KP, Padnick-Silver L, Stuertz N, Francis-Sedlak M, Holt RJ. Quality of life in patients with chronic thyroid eye disease in the United States. Ophthalmol Ther. 2021;10(4):975\u201387.","journal-title":"Ophthalmol Ther"},{"issue":"24","key":"1516_CR16","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.182352","volume":"9","author":"DW Kim","year":"2024","unstructured":"Kim DW, Kim S, Han J, et al. Transcriptomic profiling of thyroid eye disease orbital fat demonstrates differences in adipogenicity and IGF-1R pathway. JCI Insight. 2024;9(24):e182352.","journal-title":"JCI Insight"},{"key":"1516_CR17","unstructured":"Amgen Inc. Tepezza\u00ae\u00a0(teprotumumab) [prescribing information]. 2025. https:\/\/www.pi.amgen.com\/united_states\/tepezza\/tepezza_fpi_english.pdf. Accessed Sept 25, 2025."},{"key":"1516_CR18","unstructured":"Amgen Inc. Tepezza\u00ae (teprotumumab) [summary of product characteristics]. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/tepezza-epar-product-information_en.pdf. Accessed Sept 25, 2025."},{"issue":"4","key":"1516_CR19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A, et al. Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med. 2020;382(4):341\u201352.","journal-title":"N Engl J Med"},{"issue":"18","key":"1516_CR20","doi-asserted-by":"publisher","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, et al. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017;376(18):1748\u201361.","journal-title":"N Engl J Med"},{"key":"1516_CR21","volume":"55","author":"Y Hiromatsu","year":"2025","unstructured":"Hiromatsu Y, Ishikawa E, Kozaki A, et al. A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients. Lancet Reg Health West Pac. 2025;55:101464.","journal-title":"Lancet Reg Health West Pac"},{"issue":"5","key":"1516_CR22","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1097\/IOP.0000000000001292","volume":"35","author":"S Ugradar","year":"2019","unstructured":"Ugradar S, Goldberg RA, Rootman DB. Bony orbital volume expansion in thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2019;35(5):434\u20137.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"4S","key":"1516_CR23","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1097\/IOP.0000000000001139","volume":"34","author":"LC Siakallis","year":"2018","unstructured":"Siakallis LC, Uddin JM, Miszkiel KA. Imaging investigation of thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2018;34(4S):S41\u201351.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"5","key":"1516_CR24","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1007\/s00330-014-3103-3","volume":"24","author":"LS Politi","year":"2014","unstructured":"Politi LS, Godi C, Cammarata G, et al. Magnetic resonance imaging with diffusion-weighted imaging in the evaluation of thyroid-associated orbitopathy: getting below the tip of the iceberg. Eur Radiol. 2014;24(5):1118\u201326.","journal-title":"Eur Radiol"},{"issue":"2","key":"1516_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/bjophthalmol-2020-317806","volume":"106","author":"AP Jain","year":"2022","unstructured":"Jain AP, Gellada N, Ugradar S, Kumar A, Kahaly G, Douglas R. Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease. Br J Ophthalmol. 2022;106(2):165\u201371.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1516_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010016","volume":"10","author":"K Gontarz-Nowak","year":"2020","unstructured":"Gontarz-Nowak K, Szychli\u0144ska M, Matuszewski W, Stefanowicz-Rutkowska M, Bandurska-Stankiewicz E. Current knowledge on Graves\u2019 orbitopathy. J Clin Med. 2020;10(1):16.","journal-title":"J Clin Med"},{"key":"1516_CR27","doi-asserted-by":"crossref","unstructured":"Kozaki A, Takahashi Y, Tajiri Y, et al. Reduction in extraocular muscle and orbital fat volumes after teprotumumab treatment in Japanese patients with thyroid eye disease: an exploratory magnetic resonance imaging analysis from the OPTIC-J trial. Jpn J Ophthalmol. 2026;70(5):1089\u201398.","DOI":"10.1007\/s10384-026-01372-x"},{"issue":"5","key":"1516_CR28","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1167\/iovs.07-1030","volume":"49","author":"NI Regensburg","year":"2008","unstructured":"Regensburg NI, Kok PH, Zonneveld FW, et al. A new and validated CT-based method for the calculation of orbital soft tissue volumes. Invest Ophthalmol Vis Sci. 2008;49(5):1758\u201362.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"1516_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/IOP.0000000000002991","volume":"42","author":"N Yuksel","year":"2026","unstructured":"Yuksel N, Balaban M, Sozeri A, Mendi ZN, Guler F. Lacrimal gland fibrosis in patients with moderate-to-severe thyroid eye disease. Ophthalmic Plast Reconstr Surg. 2026;42(1):65\u201370.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"8","key":"1516_CR30","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1007\/s00417-024-06424-x","volume":"262","author":"X Liao","year":"2024","unstructured":"Liao X, Aljufairi F, Sebastian JU, et al. Investigation of lacrimal gland and extraocular muscle in thyroid eye disease patients with severe subjective dry eye disease: a multiparametric magnetic resonance imaging study. Graefes Arch Clin Exp Ophthalmol. 2024;262(8):2651\u20139.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"1516_CR31","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1089\/thy.2012.0119","volume":"22","author":"N Matheis","year":"2012","unstructured":"Matheis N, Okrojek R, Grus FH, Kahaly GJ. Proteomics of tear fluid in thyroid-associated orbitopathy. Thyroid. 2012;22(10):1039\u201345.","journal-title":"Thyroid"},{"key":"1516_CR32","first-page":"57","volume":"9","author":"JH Selter","year":"2015","unstructured":"Selter JH, Gire AI, Sikder S. The relationship between Graves\u2019 ophthalmopathy and dry eye syndrome. Clin Ophthalmol. 2015;9:57\u201362.","journal-title":"Clin Ophthalmol"},{"issue":"1","key":"1516_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-84661-4","volume":"11","author":"Y Takahashi","year":"2021","unstructured":"Takahashi Y, Lee PAL, Vaidya A, Kono S, Kakizaki H. Tear film break-up patterns in thyroid eye disease. Sci Rep. 2021;11(1):5288.","journal-title":"Sci Rep"},{"issue":"4","key":"1516_CR34","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1111\/ceo.14208","volume":"51","author":"S Ugradar","year":"2023","unstructured":"Ugradar S, Zimmerman E, Parunakian E, Kang J, Cockerham K, Douglas RS. Change in lacrimal gland volume and aqueous tear production following treatment with teprotumumab. Clin Exp Ophthalmol. 2023;51(4):339\u201348.","journal-title":"Clin Exp Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01516-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-026-01516-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-026-01516-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T12:53:58Z","timestamp":1791291238000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-026-01516-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":34,"alternative-id":["1516"],"URL":"https:\/\/doi.org\/10.1007\/s40123-026-01516-9","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"assertion":[{"value":"9 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shoaib Ugradar is a consultant for Viridian Therapeutics and previously consulted for Amgen Inc. Ada Kumar was an employee of Amgen Inc. and owns stock, they are now affiliated with Latigo Biotherapeutics, Thousand Oaks, CA, USA. Zhenxun Wang is an employee of Amgen Inc. and owns stock. Michael Karon was an employee of Amgen Inc. at the time of this study and is now affiliated with Aura Biosciences Inc., Boston, MA, USA. Prem S. Subramanian receives institutional research funding from Amgen Inc., is a consultant for Alumis, Amgen Inc., Kriya Therapeutics, Tourmaline Bio, and Viridian Therapeutics, and serves on a data safety monitoring board for argenx. Sara T. Wester is a consultant for Amgen Inc., argenx, Kriya Therapeutics, Immunovant, Lassen Therapeutics, and Sling Therapeutics and participates in funded research for Amgen Inc., Immunovant, Lassen Therapeutics, Sling Therapeutics, and Tourmaline Bio.","order":1,"name":"Ethics","label":"Conflicts of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was approved by the US Food and Drug Administration as well as the institutional review board or independent ethics committee at each trial site. Written informed consent was provided by all patients prior to their participation in this trial. The trial adhered to the International Conference on Harmonisation Good Clinical Practice guidelines and the principles of the Declaration of Helsinki.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}